LONDON --(Business Wire)--
The 2010 Ewing's Sarcoma treatments market was valued at $7.4million, according to a new report on companiesandmarkets.com. It is estimated that by 2017 the market will attain a value of $9.4million, representing a growth rate of 3.4% p/a. Growth is restricted by late disease diagnosis and slow increases in levels of incidence.
Ewing's Sarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017
http://www.companiesandmarkets.com/Market-Report/ewing-s-sarcoma-therapeutics-pipeline-assessment-and-market-forecasts-to-2017-619814.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2
The market for Ewing's sarcoma treatments is fairly small, with relatively low levels of incidence compared with other cacers, and represents a distinct opportunity for pharmaceutical companies to expand their profiles. Only one drug is currently approved for treatment - Cosmegen (dactinomycin) - but is no longer in use because of poor efficacy and safety reports.
Other Ewing's sarcoma treatments which are 'off-label' include Vepesid (etoposide); Oncovin (vincristine); Ifex (ifosfamide); Adriamycin (doxorubicin) and Cytoxan/Neosar (cyclophosphamide). All have shown acceptable results, but there is still an unmet need for Ewing's sarcoma therapies which offer safe and effective treatment with new modes of action.
To address this need, pharmaceutical companies have developed several first-in-class molecules for the treatment of Ewing's Sarcoma, such as Yondelis, Zalypsis, sunitinib (Sutent), dasatinib (Sprycel), ganitumab and cixutumumab.
The 69 page report, published in July 2011 report comprises 69 pages of comprehensive evaluation of the Ewing's Sarcoma therapeutic market, including historic and forecast data (2005-2017). Seven major geographies are studied: France, Italy, Germany, Spain, Japan, UK and US. Company profiles are included for Amgen Inc, Eli Lilly and Company and PharmaMar.
...